Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $50,966.04 in Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jacquelyn Sumer sold 3,742 shares of Cullinan Therapeutics stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total value of $50,966.04. Following the completion of the sale, the insider directly owned 131,690 shares in the company, valued at approximately $1,793,617.80. This represents a 2.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Cullinan Therapeutics Stock Up 0.6%

Shares of CGEM opened at $14.36 on Thursday. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $14.56. The stock has a market capitalization of $848.39 million, a P/E ratio of -4.34 and a beta of -0.09. The company has a 50 day moving average of $11.50 and a 200-day moving average of $9.31.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Neutral Sentiment: Recent short-interest data for CGEM appears unreliable (reports show 0 shares and NaN change), so there’s no clear evidence of rising short interest to explain price moves — treat that data as a likely reporting glitch.
• Neutral Sentiment: Broader market weakness (e.g., a sharp pullback in Bitcoin this month) can contribute to risk-off flows in small-cap and biotech stocks, but this is an indirect factor. Bitcoin article
• Negative Sentiment: Multiple insiders sold shares on Feb. 24 — combined ~27,051 shares (~$390.6k at ~ $14.47 average). CEO Nadim Ahmed sold 13,515 shares (≈$195.6k), reducing his stake by ~3.34%. These sizable, contemporaneous sales by the CEO and other executives can be perceived negatively by the market as signal of insider profit-taking or reduced conviction. SEC filings: Ahmed filing, Sumer filing, Jones filing, Michaelson filings

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd lifted its position in Cullinan Therapeutics by 62.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after acquiring an additional 1,036 shares during the last quarter. CWM LLC increased its stake in shares of Cullinan Therapeutics by 51.5% during the fourth quarter. CWM LLC now owns 3,876 shares of the company’s stock worth $40,000 after purchasing an additional 1,318 shares during the period. Signaturefd LLC lifted its holdings in Cullinan Therapeutics by 689.7% during the 4th quarter. Signaturefd LLC now owns 4,130 shares of the company’s stock worth $43,000 after purchasing an additional 3,607 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after purchasing an additional 2,523 shares during the period. Finally, Quarry LP bought a new stake in Cullinan Therapeutics in the 4th quarter valued at $99,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright boosted their price target on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Wall Street Zen cut Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Citigroup started coverage on Cullinan Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $33.00 price target for the company. Morgan Stanley reiterated an “overweight” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a research note on Thursday, January 8th. Finally, Wedbush increased their price objective on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.33.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.